semaglutide cardiovascular outcomes 2025 news today A new analysis of the SELECT trial confirms that lowers the risk of major heart problems in people who are overweight or obese and already have heart disease, even if they Lower risk of cardiovascular events

Introduction Constipation is one of the most persistent side effects of GLP1 medications, affecting approximately 24 percent of patients on semaglutide 2.4 mg in the STEP 1 trial (Wilding et al., New England Journal of Medicine , 2021)

Ali Reza A, Nasrin MS, Hossen MA, Rahman MA, Jantan I, Haque MA, et al

A.Al-SharifG

Although Ozempic may offer weight loss benefits, it is not recommended for use in non-diabetic individuals due to potential risks and the absence of official approval for this purpose

In some cases, motor deficits or loss of function may develop if the tumor affects motor nerves

In the middle, branded Wegovy and Zepbound through telehealth land between $349 and $1,060 depending on the platform